Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Investor Presentation (July 2019)
21 slides from Rhythm Biosciences's investor presentation, July 2019
Slide 1: Early detection of colorectal cancer using a simple and low cost blood test
A Medical Diagnostics Technology Company Early detection of colorectal cancer using a simple and low cost blood test Corporate presentation July 2019 ASX: RHY © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL
Slide 2: Table of contents
Table of contents Rhythm Corporate overview 3 ColoSTAT® by Rhythm Biosciences 4 Colorectal Cancer 5 Introduction 5 Early detection 6 Global screening 7 Why aren’t people screening 8 Journey with current testing 9 Journey with ColoSTAT® 10 Effectiveness 11 Competitive advantage 12 Competitive landsca
Slide 3: Corporate Overview
Corporate Overview Rhythm Biosciences Financial Information – A medical diagnostics technology ASX Ticker RHY company Share Price (22 Jul 2019) $0.21 12-Month Range $0.13 - 0.23 Rhythm Biosciences is positioning itself as a new Shares on Issue ~100.7M generation medical diagnostics technology Market
Slide 4: ColoSTAT® by Rhythm Biosciences
ColoSTAT® by Rhythm Biosciences ColoSTAT® A simple, accurate and low cost blood test for the early detection of colorectal cancer, suitable for the global mass market ColoSTAT® is An Australian A simple blood Low cost and designed for the innovation test using protein patient friendly - detection of
Slide 5: Colorectal Cancer: Introduction
Colorectal Cancer: Introduction Colorectal cancer is the second Curable in over 90% of cases if The current standard diagnostic largest cause of cancer-related detected early, this drops to screening test is the Faecal deaths in the industrialized around 10% if detected late Immunochemical Test (FIT
Slide 6: Early detection is the key to survival
Early detection is the key to survival Governments currently fund screening for 50-74 year olds However, there are currently over 132,628,000 million people who fall within the at-risk age not being screened each year © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL 6
Slide 7: Global screening of 50-74 year olds
Global screening of 50-74 year olds Annual Estimated screening compliance by market 50-74 population 153,400,000 95,108,000 50-74 population unscreened 91,200,000 33,744,000 63 38 50-74 population 6,400,000 unscreened America % Europe % 3,776,000 unscreened 41 % Australia Total 50-74 Total 50-74 uns
Slide 8: Why aren't people being screened?
Why aren’t people being screened ? Acceptability: Aversion to the handling of faeces Complexity: Multiple steps, several pieces of equipment Based on current FIT Avoidance: Dislike colonoscopy and bowel preparation testing Suitability: FIT not suitable for some populations (e.g. GI bleeding) Suitabi
Slide 9: ColoSTAT®: patient friendly = increased compliance – Today FIT testing
ColoSTAT® : patient friendly = increased compliance Today – FIT testing FIT Testing Central FIT Sample Pathology Collection lab Process Diagnostic assessment to GP * Multi step faecal collection, packaging over at least 2 days then posting sample back to a central laboratory. Obligation on patient t
Slide 10: ColoSTAT®: patient friendly = increased compliance – With ColoSTAT®
ColoSTAT® : patient friendly = increased compliance “83% of unscreened participants preferred a blood test over a faecal test” * With ColoSTAT® GP referral Any Blood draw Pathology lab Diagnostic assessment to GP ColoSTAT® - a less involved and simpler process that has the potential to increase comp
Slide 11: ColoSTAT® effectiveness
ColoSTAT® effectiveness Sensitivity of ColoSTAT® at Specificity of 95% FIT (80ug/g) (91.9% specificity) ColoSTAT (95% specificity) 90.00% 83% 80% 80.00% 73% 74% 71% 70.00% 68% 63% 58% 58% 60.00% 53% 50.00% 40.00% 30.00% 20.00% 10.00% 0.00% All stage cancer Stage 1 Stage 2 Stage 3 Stage 4 Fung et al.
Slide 12: ColoSTAT®'s competitive advantage
ColoSTAT®’s competitive advantage Rhythm Faecal Immunochemical Test (FIT) Patient Preference Patient Preference Accuracy Accuracy Early Stage Detection Early Stage Detection Affordability Affordability Simple Process Simple Process Opportunistic Screening* Opportunistic Screening* ColoSTAT®’s combin
Slide 13: Competitive Landscape – ColoSTAT®'s unique advantage
Competitive Landscape – ColoSTAT®’s unique advantage Blood based Colo Epigenomics STAT® Epi proColon® Novigenix Volition Rx ~$21m Colox® Nu.q™ private ~$190m Clinical ~$107m Genomics Colvera™ Market capitalisation of existing companies >$100m with blood based screening products private APPROACH Exac
Slide 14: Market Overview
Market Overview Estimated Screening Market Value by jurisdiction 153,400,000 potential tests $4.56 $7.67 America bn Europe bn 91,200,000 6,400,000 potential tests potential tests $320 m Australia In America, Europe and Australia alone, the potential screening market aged 50-74 is worth $12,550,000,0
Slide 15: Path to Market
Path to Market Rhythm Biosciences simple, accurate and low cost blood test will fill a unique space in the mass screening market Research & IVD kit Regulatory Reagent Market entry development development & Clinical trial submissions (cast/control studies development AU, EU, production (Europe & over
Slide 16: Go to Market Options
Go to Market Options Multiple avenues and market segments reduce risk and support a flexible and scalable business model National Screening National Program/MBS Reimbursed Secondary Triage Screening Triage • With its effectiveness and Markets • As a transition, ColoSTAT® affordability, ColoSTAT® is
Slide 17: Summary
Summary As a simple, accurate and low cost blood test, Rhythm’s ColoSTAT® has the potential to significantly increase global screening compliance and save more lives • There are over 251m people aged 50-74 in the US, EU and AU alone that are at risk and should be screened for Colorectal Cancer • Ove
Slide 18: Why Invest in Rhythm?
Why Invest in Rhythm ? 1 Significant Opportunity Mass screening market worth over $12bn for people aged 50-74 in the US, EU, and AU alone. Market wants change. 2 Sound technology Over 13 years of research and testing pioneered by the CSIRO* giving confidence in the biomarkers selected 3 Simple Busin
Slide 19: Board and Management
Board and Management A strong and experienced board & management team with proven commercial, operational and industry experience SHANE TANNER GLENN GILBERT TREVOR LOCKETT LOU PANACCIO DAVID WHITE Chairman Chief Executive Officer Technical Director Non-Executive Director Non-Executive Director • Cha
Slide 20: Glenn Gilbert CEO, Rhythm Biosciences
Glenn Gilbert CEO, Rhythm Biosciences glenn.gilbert@rhythmbio.com www.rhythmbio.com © Rhythm Biosciences Ltd. All rights reserved. CONFIDENTIAL 20
Slide 21: Disclaimer
Disclaimer • This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or unde
Rhythm Biosciences — Investor Presentation (July 2019) on 6ix